Partners undermine basilea
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica continues to be under the cosh as it responds to the double whammy of seeing ceftobiprole removed from the Swiss market at the request of its partner while Astellas has informed the company that plans to delay the start a Phase III trial of isavuconazole to treat Aspergillus infections.